Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (407 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 3.2% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 51.9% (lowers risk) · Drug's FDA history
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: therapypurposestablediagnosispatients
  Phrases that lowered it: disorderhistory ofantiviralfemalehepatitis
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 24 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 8.1% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 9754 (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Sponsor's past trials: 31 (lowers risk) · Sponsor's track record
• Responsible party: sponsor (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence NCT02111798 · started 2014 · scored riskier than 15% of active trials completed
• Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia NCT01863251 · started 2013 · scored riskier than 13% of active trials completed
• Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) NCT01449565 · started 2012 · scored riskier than 11% of active trials completed
• Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence NCT00687713 · started 2008 · scored riskier than 59% of active trials completed
• Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine NCT02357901 · started 2015 · scored riskier than 12% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.